Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Endohedral Fullerene $167,000,000/gram
View:
Post by biggdogg on Jun 07, 2024 11:26am

Endohedral Fullerene $167,000,000/gram

An endohedral fullerene is different than fullerne. RC and Voy are doing ground breaking work, that has never been achieved in history. The technology side of Voyaguer drug development, with Vanadium inside a C60, will gain traction once the market understands the magnitude of what they are doing. $167M a gram is what it costs the industry, $0 is what it cost Voyaguer. What an amazing partnership, the value is emmense. Toyota are no dummies, looks like Voyaguer are a little smarter than most thought as well.
https://arstechnica.com/science/2015/12/oxford-company-now-selling-endohedral-fullerenes-priced-at-110-million-per-gram/
Comment by postie1 on Jun 07, 2024 12:58pm
Just for the record, the last sale for VM was at .08 but is being hidden on the dark boards(manipulation ?) And stuff like this is why I am of the belief that VM has a big target on its' back and there will be a buyout attempt before things get moving along too far..How much are VMs licences alone worth plus the deposit. I am taking a guess that it is more than what the market is valuing VM ...more  
Comment by whitenorth72 on Jun 07, 2024 1:05pm
BMO has full control of the share price and might be shaking the tree to get some cheap shares from the traders that made a few bucks this week. Thats my uneducated guess.lol
Comment by postie1 on Jun 07, 2024 1:15pm
Not going to disagree with you on that.
Comment by postie1 on Jun 07, 2024 3:14pm
Well, I guess the fact that it was BMO who sold down on small volume and it BMO that ran it back up on bigger volume(over 300,000 at this moment) kind of backs you up. Shake that tree is what the pros' do. Volume of sells built and trigger pulled without moving price from original. That being said I wonder if that 300,000 sell order(s) were blocks.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1